Lipella Pharmaceuticals Inc. Common Stock LIPO · Stock Open Lipella Pharmaceuticals Inc. Common Stock in new tab
Lipella Pharmaceuticals Inc. Common Stock Analysis (LIPO)
Is Lipella Pharmaceuticals Inc. Common Stock a good investment? Lipella Pharmaceuticals Inc. Common Stock (LIPO) is currently trading at 0.000500 USD.
Earnings Schedule: Lipella Pharmaceuticals Inc. Common Stock is expected to release its next earnings report on Dec. 2, 2026. The market consensus estimate for Forward EPS is -3.20.
Investor FAQ
Does Lipella Pharmaceuticals Inc. Common Stock pay a dividend?
No, it does not currently pay a dividend.
What asset class is Lipella Pharmaceuticals Inc. Common Stock?
Lipella Pharmaceuticals Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Dec. 2, 2026. The company currently has a trailing EPS of -2.26.
Company Profile
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It develops LP-10, a formulation of tacrolimus for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; LP-410, an oral liposomal formulation of tacrolimus to treat oral graft-versus-host disease; and LP-50, an intravesical formulation of immunoglobulins for the treatment of non-muscle invasive bladder cancer. Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania. On March 30, 2026, Lipella Pharmaceuticals Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Western District of Pennsylvania.
| Split Date | Split Ratio to 1 |
|---|---|
| Nov. 8, 2024 | Needs review |
Community Discussion